Molecular Formula	C17H26N2O
Molecular Weight	274.4
Structure
State	solid
Clearance	* 387 +/- 107 mL/min * unbound plasma clearance=7.2 +/- 1.6 L/min
Route of elimination	Ropivacaine is extensively metabolized in the liver, predominantly by aromatic hydroxylation mediated by cytochrome P4501A to 3-hydroxy ropivacaine. After a single IV dose approximately 37% of the total dose is excreted in the urine as both free and conjugated 3-hydroxy ropivacaine. In total, 86% of the ropivacaine dose is excreted in the urine after intravenous administration of which only 1% relates to unchanged drug.
Protein binding	94%, mainly to a1-acid glycoprotein
Half life	Approximately 4.2 hours.
Absorption	Bioavailability is 87%–98% following epidural administration.

Pictogram	Signal	Statements	Precautionary Statement Codes
	Warning	Aggregated GHS information provided by 13 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (92.31%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (76.92%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (76.92%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H332 (69.23%): Harmful if inhaled [Warning Acute toxicity, inhalation] H412 (84.62%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
	Danger	Aggregated GHS information provided by 49 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (12.24%): Harmful if swallowed [Warning Acute toxicity, oral] H318 (81.63%): Causes serious eye damage [Danger Serious eye damage/eye irritation] H412 (12.24%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P264, P270, P273, P280, P301+P312, P305+P351+P338, P310, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
	Warning	Aggregated GHS information provided by 3 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H412 (100%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P264, P270, P273, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism	Test type	Route	Dose (normalized dose)	Effect	Source
rat	LD50	parenteral	56mg/kg (56mg/kg)		Anesthesiology. Vol. 89, Pg. 1199, 1998.

Labour pain

Pregnancy

Procedural pain

Abnormal labour (0.017)

Vomiting neonatal (0.017)

Abdominal distension

Abdominal pain

Agitation

Alanine aminotransferase increased

Anaemia

Anxiety

Apgar score low

Arrhythmia

Arthralgia

Back pain

Body temperature decreased

Body temperature increased

Bradycardia

Bradycardia foetal

Breast disorder

Breast feeding

Bronchospasm

Chest pain

Chills

Confusional state

Constipation

Dermatitis

Diarrhoea

Dizziness

Dyspepsia

Dyspnoea

Dysuria

Feeling abnormal

Fever neonatal

Foetal distress syndrome

Gastrointestinal pain

Haematuria

Headache

Hyperhidrosis

Hypertension

Hypoaesthesia

Hypoglycaemia neonatal

Hypokalaemia

Hypotension

Hypothermia

Hypoxia

Infection

Injection site reaction

Jaundice neonatal

Micturition disorder

Musculoskeletal discomfort

Myalgia

Nausea

Neonatal infection

Neonatal tachypnoea

Oedema peripheral

Pain

Paraesthesia

Paresis

Post procedural complication

Pruritus

Purpura

Rash

Respiratory disorder neonatal

Rhinitis

Somnolence

Tachycardia

Tachycardia foetal

Tachypnoea

Tremor

Urinary incontinence

Urinary retention

Urinary tract infection

Vascular purpura

Vomiting

(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilid	(-)-1-Propyl-2',6'-pipecoloxylidide	(-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide	(2S)-N-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide	(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(S)-(-)-1-propyl-2',6'-pipecoloxylidide	(S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide	(S)-Ropivacaine
057R954	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-	7IO5LYA57N
84057-95-4	98717-15-8	A840710
AB00698466-07	AB00698466_10	AK326168
AKOS017343283	AL-381	AS-35173
BBL102321	BIDD:GT0203	C07532
CHEBI:8890	CHEMBL1077896	D08490
DB00296	DTXSID4040187	GTPL7602
K500	L-N-n-propylpipecolic acid-2,6-xylidide	LEA-103
LEA-103 HCl	NCGC00164597-01	Narop
Naropin	Naropin (TN)	Noropine
Q-201677	Q279504	Ropivacaina
Ropivacaina [INN-Spanish]	Ropivacaina [Spanish]	Ropivacaine
Ropivacaine (INN)	Ropivacaine [INN:BAN]	Ropivacaine [INN]
Ropivacaine base	Ropivacainum	Ropivacainum [INN-Latin]
S-Ropivacaine	SC-23114	SCHEMBL33292
STL556120	UNII-7IO5LYA57N	ZINC897002
ZKMNUMMKYBVTFN-HNNXBMFYSA-N

DrugBank Name	Ropivacaine
DrugBank	DB00296
CAS Number	132112-35-7, 84057-95-4, 98717-15-8
PubChem Compound	175805
KEGG Compound ID	C07532
KEGG Drug	D08490
PubChem.Substance	46504712
ChEBI	8890
PharmGKB	PA451271
ChemSpider	153165
TTD	DAP001230
Wikipedia	Ropivacaine
DPD	11081